53991-48-3

Basic information

• Product Name: androst-5-ene-3-beta,17-alpha-diol di(acetate)
• Synonyms: androst-5-ene-3-beta,17-alpha-diol di(acetate);Einecs 258-906-9
• CAS NO: 53991-48-3
• Molecular Formula: C₂₃H₃₄O₄
• Molecular Weight: 374.51366
• EINECS: 258-906-9
• Mol File: 53991-48-3.mol
• Article Data: 6

Chemical Properties

• Melting Point: 166-167 °C(Solv: ethanol (64-17-5))
• Boiling Point: 448.9°Cat760mmHg
• Flash Point: 215.1°C
• Appearance: /
• Density: 1.12g/cm³
• CAS DataBase Reference: androst-5-ene-3-beta,17-alpha-diol di(acetate)(CAS DataBase Reference)
• NIST Chemistry Reference: androst-5-ene-3-beta,17-alpha-diol di(acetate)(53991-48-3)
• EPA Substance Registry System: androst-5-ene-3-beta,17-alpha-diol di(acetate)(53991-48-3)

Safety Data

• Hazardous Substances Data: 53991-48-3(Hazardous Substances Data)

Upstream product

• 40768-03-4 androst-5-ene-3β,17α-diyl 3-acetate 17-benzoate 
• 853-23-6 prasterone acetate 
• 1259-22-9 5-androstene-3β,17β-diol 3-acetate 17-p-toluene-δ-sulfonate 
• 108-24-7 acetic anhydride 
• 100428-85-1 17α-hydroxyandrost-5-en-3β-yl 3-acetate 
• 1963-03-7 androst-5-ene-3β,17α-diol 
• 521-17-5 androst-5-ene-3β,17β-diol 
• 64-19-7 acetic acid 

Downstream Products

• 1963-03-7 androst-5-ene-3β,17α-diol 

Relevant articles and documents

ESTROGEN RECEPTOR MODULATORS

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Paget’s disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, inflammation, inflammatory bowel disease and cancer, in particular of the breast, uterus and prostate.

ESTROGEN RECEPTOR MODULATORS

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Paget’s disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, inflammation, inflammatory bowel disease, sexual dysfunction, hypertension, retinal degeneration and cancer, in particular of the breast, uterus and prostate.

Chloro- or bromo-trimethylsilane induced rapid and quantitative acid-ester conversion for steroid based alcohols with various carboxylic acids under solvent free conditions

Steroid based higher alcohols are rapidly esterified in quantitative yield with a number of carboxylic acids in the presence of TMSCl or TMSBr generally under solvent free conditions.